A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...